Authors


Dr. Robert Schwartzman

Latest:

Recent US Supreme Court decisions narrow life-sciences patentability claims

Industry response may be to keep more innovations as trade secrets


Gregg Fisher

Latest:

Six Steps to Driving Patient Support Program Enrollment

Although there is no ‘one size fits all’ solution, the process is influenced by factors such as lifestyle stage, competitive outlook, and market constraints.


Partha Anbil, IBM

Latest:

Optimizing hub services with the power of cloud and mobile

Cloud-based IT technologies are a natural fit for patient-support hubs


Michael Abrams, Numerof & Associates

Latest:

Key Elements for Success in Pharma M&A Integration

How can buyers maximize the value of their acquisitions?


By Haris Kamal, Verify Brand

Latest:

GS1 standards are vital for pharma serialization

‘Future proof’ your implementation by adhering to industry standards



Shlomi Aflalo, Helparound.co

Latest:

Online personal data will be a boon for patient support

Specialty-pharma support providers have a potential benefit in behavioral targeting insights


By Marci Juneau

Latest:

First physicians, now patients: Risk avoidance in patient support programs

A look into the growing compliance risks associated with patient services



Adam J. Fein, PhD, Pembroke Consulting, Inc.

Latest:

The Battle for Control of Specialty Drugs

Specialty distributors, specialty pharmacies and healthcare providers are all competing for a dominant position in drug delivery and reimbursement


Marianne Messer, Elsevier's Gold Standard

Latest:

Analyzing drug-pricing mechanisms

Pricing systems in US drug supply chain have many limitations; an analytics-based method might avoid some of them



Tommy Bramley, Lash Group

Latest:

Patient support in the time of Covid-19

Five ways to adapt manufacturer-sponsored programs


Thomas Carey, Sunstein Kann Murphy & Timbers LLP

Latest:

Generic Manufacturers Gain Another Advantage in Disputing Drug Patents

FDA sets a precedent for granting generic approvals even when initial litigation goes against the generic manufacturer


Don Schenker, Synergistix

Latest:

Make your CRM vendor a true partner to your sales team

Today's cloud-based, fast-evolving CRM systems call for a closer partnership between vendor and client


Kady Bruce, Wolf Greenfield

Latest:

Protecting pharmaceutical exclusivity: Avoiding the hidden dangers of double patenting

Multiple patents contribute to a robust portfolio; however, each patent that issues can potentially become a landmine to another



Jessica Black, Xcenda

Latest:

Manufacturers can support the ICD-10 transition

Healthcare's conversion to a new coding system can affect drug prescribing. Here's what you need to know



Jeffrey Jung

Latest:

Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of Capital

Investment funds have developed an interest in trading capital for royalties on drug commercializations


By Craig Voellmicke, CSP Technologies, Inc.

Latest:

Active packaging protects oral solid formulations

New technologies offer improved shelf life for moisture- and oxygen-sensitive oral solids



By Abbey Bernardi, LexisNexis Risk Solutions Health Care

Latest:

The Truth Behind IDNs: Is It Who You Know, or What You Know?

Connecting with buying influences in integrated delivery networks is a challenge


Chris Nickum, IMS Health Consulting

Latest:

The Drive to Develop New Commercial Models

Industry’s coming challenges will force dramatic change on how products are brought to market and businesses are sustained. Industry leaders have already started the process


Dean Erhardt, D2 Consulting

Latest:

REMS Drives Manufacturer-Specialty Pharmacy Relationships

Specialty pharmacies are competing to position themselves as the best partners for manufacturers dealing with high-touch, high-risk products


Kevin L. Jones, Faegre Baker Daniels

Latest:

Pharma in China--calculated risk gone wrong

Doing business in China is undergoing important changes


Ferdi Steinmann, OpenText

Latest:

From pain to practice?

Key lessons for the supply chain post-pandemic


Promotional Affairs, AstraZeneca

Latest:

AstraZeneca's Principles for Product-Related Online Communications

Industry anticipates meaningful guidance from FDA on use of social media


Jennifer Goldsmith, Veeva Systems

Latest:

Cloud-based services manage regulated content better

Unifying the management of clinical research documentation and marketing content saves time and accelerates speed-to-therapy


Michael N. Abrams, MA, Numerof & Associates

Latest:

Pharma's stake in comparative effectiveness research

When drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful

© 2024 MJH Life Sciences

All rights reserved.